Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Gabelli lowered their FY2017 earnings per share (EPS) estimates for shares of Henry Schein in a research note issued to investors on Wednesday. Gabelli analyst K. Kedra now expects that the company will earn $7.25 per share for the year, down from their previous forecast of $7.30. Gabelli also issued estimates for Henry Schein’s FY2018 earnings at $8.10 EPS, FY2019 earnings at $9.05 EPS, FY2020 earnings at $9.95 EPS and FY2021 earnings at $10.95 EPS.
Other equities research analysts also recently issued research reports about the company. Jefferies Group LLC restated a “hold” rating and set a $177.00 price target on shares of Henry Schein in a report on Friday, July 21st. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a report on Tuesday, April 25th. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. Barrington Research upped their price target on Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Finally, BidaskClub downgraded Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $185.56.
Shares of Henry Schein (NASDAQ HSIC) opened at 170.58 on Thursday. The stock has a market cap of $13.49 billion, a price-to-earnings ratio of 24.93 and a beta of 1.09. The firm has a 50-day moving average price of $181.54 and a 200-day moving average price of $175.12. Henry Schein has a 1-year low of $146.23 and a 1-year high of $186.99.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, topping analysts’ consensus estimates of $1.73 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the firm posted $1.64 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Waldron LP purchased a new stake in shares of Henry Schein during the first quarter worth about $286,000. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Henry Schein by 2.0% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,147 shares of the company’s stock worth $341,000 after buying an additional 43 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Henry Schein during the first quarter worth about $207,000. Wagner Bowman Management Corp purchased a new stake in shares of Henry Schein during the first quarter worth about $222,000. Finally, State of Alaska Department of Revenue boosted its stake in shares of Henry Schein by 264.7% in the first quarter. State of Alaska Department of Revenue now owns 23,597 shares of the company’s stock worth $4,010,000 after buying an additional 17,126 shares during the period. 90.87% of the stock is owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.